Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021.

We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy.

Links to papers below:
1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer NEJM 2023

2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
NEJM 2021

Even better on our YouTube channel

About GU Cast Journal Club:
Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.